Contraindications for giritinib

Gilitinib is a targeted therapy for FLT3 mutation-positive acute myeloid leukemia (AML). Although giritinib has made significant progress in the treatment of AML, in some specific cases, the use of giritinib may bring risks, so there are some contraindications for its use. The following are some possible medication contraindications and related precautions:

1.History of allergy: Giritinib should be contraindicated in patients with a history of allergy to giritinib or similar drugs. Before receiving treatment, patients should inform their doctor of their allergy history and follow their doctor's recommendations.

2.Serious heart disease: Giritinib may cause cardiotoxicity, leading to arrhythmias or cardiovascular events. Therefore, patients with severe heart disease (such as severe arrhythmia, myocardial infarction, etc.) should avoid using giritinib or use it with caution under the guidance of a cardiologist.

3.QTinterval prolongation: Giritinib may cause QT interval prolongation, thereby increasing the risk of arrhythmia. Therefore, before starting treatment, patients should have an electrocardiogram and rule out prolongation of the QT interval. At the same time, the QT interval needs to be closely monitored during treatment, and the dose should be adjusted or treatment stopped in time to avoid serious arrhythmias.

4.Hepatic Impairment: Girritinib should be used with caution in patients with severe hepatic impairment as its metabolism may be primarily through the liver. Before starting treatment, patients should undergo liver function tests and adjust the dose or monitor the blood concentration of the drug based on the test results.

5.Pregnancy and lactation: Giritinib may cause harm to the fetus, so pregnant women should avoid using giritinib. During treatment, female patients need to take effective contraceptive measures to prevent unwanted pregnancy. At the same time, giritinib may be secreted into breast milk, so breastfeeding women should avoid using this drug or stop breastfeeding under the guidance of a doctor.

6.Children and Adolescents: There are currently insufficient data to support the safety and effectiveness of gilitinib in children and adolescents. Therefore, the use of giritinib in patients <18 years of age is not recommended.

7.Other drug interactions: Giritinib may interact with other drugs, affecting their efficacy or increasing the risk of adverse reactions. Before starting treatment, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements, to avoid potential interactions.

To sum up, giritinib, as a targeted therapy, may have contraindications in some specific circumstances, such as history of allergies, severe heart disease, prolongation of QT interval, liver function impairment, pregnancy and lactation, children and adolescents, and other drug interactions. Patients should receive a thorough clinical evaluation before receiving treatment and follow their physician's recommendations and prescriptions.